2025
Factors associated with decreased treatment intensity in patients with metastatic colon cancer: A real world analysis.
Forman R, Wang R, Yasin F, Kwaramba T, Lacy J, Ma X, Dinan M. Factors associated with decreased treatment intensity in patients with metastatic colon cancer: A real world analysis. Journal Of Clinical Oncology 2025, 43: 11168-11168. DOI: 10.1200/jco.2025.43.16_suppl.11168.Peer-Reviewed Original ResearchMetastatic colon cancerNon-intensive therapyNational Comprehensive Cancer NetworkPoor performance statusIntensive therapyFlatiron Health electronic health record-derived deidentified databaseColon cancerIntensive first-line therapyUndertreatment of older patientsNational Comprehensive Cancer Network guidelinesOdds ratioAssociated with treatment choiceFirst-line therapyAssociated with female sexComprehensive Cancer NetworkRetrospective cohort studyYear of diagnosisShorter overall survivalNon-frail patientsOlder ageNon-frailMultivariate logistic regressionEstimate odds ratiosAssociated with receiptTreatment intensity
2024
Characterization of time toxicity in older patients with metastatic breast cancer
Atre S, Soulos P, Kuderer N, Gross C, Baum L, Dinan M, Lustberg M. Characterization of time toxicity in older patients with metastatic breast cancer. Breast Cancer Research And Treatment 2024, 207: 541-550. PMID: 38816556, DOI: 10.1007/s10549-024-07379-7.Peer-Reviewed Original ResearchMetastatic breast cancerBone-modifying agentsComorbid medical conditionsOlder patientsBreast cancerRetrospective cohort studySEER-Medicare databaseTreatment typeCancer treatment modalityTreatment modalitiesSEER-MedicareCohort studyUnadjusted analysisPatientsAge-related impactCancer treatmentComorbiditiesDay patientsCancerRadiotherapyOlder ageMedical conditionsToxicityTreatmentSociodemographic factors
2023
Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy.
Rahman S, Long J, Westvold S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy. JCO Oncology Practice 2023, 19: 28-28. DOI: 10.1200/op.2023.19.11_suppl.28.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsInitial treatmentRetrospective cohort studyUse of immunotherapyYear of diagnosisRenal cell carcinomaDirect treatment costsMean Medicare paymentsMedicare paymentsMedicare Part DInitial therapyCohort studyMetastatic diagnosisCell carcinomaCombination therapyImmunotherapyMedicare beneficiariesPatientsAge 65Disease controlOlder ageStudy periodTherapyDiagnosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply